RESUMO
The capacity of a new drug containing ultra-low doses of antibodies to cannabinoid receptor type 1 (Dietressa) to reduce body weight gain in mice on a high-calorie diet was evaluated, possible mechanisms of drug action were analyzed, and its safety (abuse potential in the reaction of self-stimulation) was evaluated. Dietressa was not inferior to sibutramine in reducing body weight gain in mice and exhibited no abuse potential.
Assuntos
Fármacos Antiobesidade/farmacologia , Anticorpos/farmacologia , Obesidade/prevenção & controle , Receptor CB1 de Canabinoide/imunologia , Redução de Peso/efeitos dos fármacos , Animais , Ciclobutanos/metabolismo , Ciclobutanos/farmacologia , Avaliação Pré-Clínica de Medicamentos , Ingestão de Alimentos/efeitos dos fármacos , Ingestão de Alimentos/fisiologia , Masculino , CamundongosRESUMO
We compared two modifications of Vogel conflict test and assessed anxyolitic activity of two drugs: diazepam (benzodiazepine anxiolitic) and tenoten (ultra-low doses of antibodies to S-100 protein) in both modifications of the test. It was found that the intensity of anxiolitic effect of the drugs depends on the conditions of Vogel test.
Assuntos
Ansiolíticos/farmacologia , Anticorpos/farmacologia , Ansiedade/tratamento farmacológico , Diazepam/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Eletrochoque , Masculino , Ratos , Privação de ÁguaRESUMO
Afala (ultralow-dose antibodies to prostate-specific antigen) injected for 60 days to rats with hormone-induced prostatitis caused by sulpiride prevented the development of prostatic hyperplasia and reduced the severity of histological changes. The effect of Afala was superior to that of the reference drug (Serenoa repens extract).